S4 Table. Relationship between AGR3 and molecular subtypes in IDC of grade I-II

| Molecular subtypes | No. | AGR3 expression, $\mathrm{n}(\%)$ |  |  | p-value |
| :--- | :--- | :--- | :--- | :--- | :--- |
|  |  | Low | High |  |  |
| Luminal A | 57 | $30(52.6)$ | $27(47.4)$ | -0.218 | $<0.001$ |
| Luminal B | 143 | $71(49.7)$ | $72(50.3)$ |  |  |
| HER2-overexpressing | 19 | $18(94.7)$ | $1(5.3)$ |  |  |
| TNBC | 41 | $33(80.5)$ | $8(19.5)$ |  |  |

p-value was calculated by Spearman's rank correlation test. AGR3, anterior gradient 3; IDC, invasive ductal carcinoma; HER2, human epidermal growth factor receptor 2; TNBC, triple-negative breast cancer.

